Cargando…

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment

BACKGROUND: Despite its recognised toxicity, antimonial therapy continues to be the first-line drug for cutaneous leishmaniasis (CL) treatment. Intralesional administration of meglumine antimoniate (MA) represents an alternative that could reduce the systemic absorption of the drug and its side effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Silva, Rosiana Estéfane, Carvalho, Janaína de Pina, Ramalho, Dario Brock, Senna, Maria Camilo Ribeiro De, Moreira, Hugo Silva Assis, Rabello, Ana, Cota, Erika, Cota, Gláucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Oswaldo Cruz, Ministério da Saúde 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722261/ https://www.ncbi.nlm.nih.gov/pubmed/29236929 http://dx.doi.org/10.1590/0074-027601700125

Ejemplares similares

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
por: Ramalho, Dario Brock, et al.
Publicado: (2018)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2016)

Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review
por: Brito, Nayara Castelano, et al.
Publicado: (2017)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis
por: Brito, Nayara C., et al.
Publicado: (2019)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil
por: Carvalho, Janaína de Pina, et al.
Publicado: (2021)

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
por: Rojas Cabrera, Ernesto, et al.
Publicado: (2022)

Development and initial validation of a cutaneous leishmaniasis impact questionnaire
por: Galvão, Endi Lanza, et al.
Publicado: (2018)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
por: Omidian, Mohammad, et al.
Publicado: (2019)

Evaluation of a new brand of immunochromatographic test for visceral leishmaniasis in Brazil made available from 2018
por: Freire, Mariana Lourenço, et al.
Publicado: (2018)

Cost-effectiveness of serological tests for human visceral leishmaniasis in the Brazilian scenario
por: Freire, Mariana Lourenço, et al.
Publicado: (2020)

How cutaneous leishmaniasis and treatment impacts in the patients’ lives: A cross-sectional study
por: Galvão, Endi Lanza, et al.
Publicado: (2019)

A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
por: Rodrigues, Bruna Côrtes, et al.
Publicado: (2020)

Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic Review
por: Cota, Gláucia F., et al.
Publicado: (2011)

Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil
por: de Assis, Tália Santana Machado, et al.
Publicado: (2022)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

Serology for visceral leishmaniasis: How trusty is the accuracy reported by the manufacturers?
por: Freire, Mariana Lourenço, et al.
Publicado: (2023)

Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis
por: Galvão, Endi Lanza, et al.
Publicado: (2017)

Performance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis
por: Freire, Mariana Lourenço, et al.
Publicado: (2019)

The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis
por: Cota, Gláucia Fernandes, et al.
Publicado: (2016)

The cure rate after different treatments for mucosal leishmaniasis in the Americas: A systematic review
por: Carvalho, Janaína de Pina, et al.
Publicado: (2022)

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil
por: Oliveira-Ribeiro, Carla, et al.
Publicado: (2021)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Economic evaluations addressing diagnosis and treatment strategies for neglected tropical diseases: an overview
por: de Assis, Tália Machado, et al.
Publicado: (2021)

The Diagnostic Accuracy of Serologic and Molecular Methods for Detecting Visceral Leishmaniasis in HIV Infected Patients: Meta-Analysis
por: Cota, Gláucia Fernandes, et al.
Publicado: (2012)

Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison
por: Cota, Gláucia F., et al.
Publicado: (2013)

Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study
por: Castro, Maria del Mar, et al.
Publicado: (2023)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Immune Activation and Bacterial Translocation: A Link between Impaired Immune Recovery and Frequent Visceral Leishmaniasis Relapses in HIV-Infected Patients
por: Silva-Freitas, Maria Luciana, et al.
Publicado: (2016)

Diagnosis of visceral and cutaneous leishmaniasis using loop-mediated isothermal amplification (LAMP) protocols: a systematic review and meta-analysis
por: Erber, Astrid Christine, et al.
Publicado: (2022)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2014)

Cost-effectiveness of a canine visceral leishmaniasis control program in Brazil based on insecticide-impregnated collars
por: de Assis, Tália Machado, et al.
Publicado: (2020)

Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate
por: Guarneri, Claudio, et al.
Publicado: (2017)

Ramsey hunt syndrome after antimonial treatment for American Cutaneous Leishmaniasis
por: Cavalcante, Melissa de Sousa Melo, et al.
Publicado: (2020)

“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia
por: Eid Rodríguez, Daniel, et al.
Publicado: (2019)

Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis
por: Bashir, Uzma, et al.
Publicado: (2019)

Anti-mitochondrial Tryparedoxin Peroxidase Monoclonal Antibody-Based Immunohistochemistry for Diagnosis of Cutaneous Leishmaniasis
por: Freire, Mariana Lourenço, et al.
Publicado: (2022)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: Ribeiro, Madelon Novato, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r336bo32ft5tc71pn1ato0khn5